Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.
Vivek A UpadhyayBruce E JohnsonAdam B LandmanMichael J HassettPublished in: JCO precision oncology (2022)
In this large cohort study of patients with solid tumors, off-label use of targeted therapy was uncommon. With that said, a notable proportion of patients had treatment durations ≥ 6 months and survivals of ≥ 2 years.